- Home
- TEAF vs MCRB Comparison
TEAF vs MCRB Comparison
Compare TEAF & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- MCRB
- Stock Information
- Founded
- TEAF 2017
- MCRB 2010
- Country
- TEAF United States
- MCRB United States
- Employees
- TEAF N/A
- MCRB N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- MCRB Health Care
- Exchange
- TEAF Nasdaq
- MCRB Nasdaq
- Market Cap
- TEAF 174.8M
- MCRB 141.9M
- IPO Year
- TEAF N/A
- MCRB 2015
- Fundamental
- Price
- TEAF $11.11
- MCRB $0.37
- Analyst Decision
- TEAF
- MCRB Hold
- Analyst Count
- TEAF 0
- MCRB 5
- Target Price
- TEAF N/A
- MCRB $4.00
- AVG Volume (30 Days)
- TEAF 56.1K
- MCRB 1.3M
- Earning Date
- TEAF 01-01-0001
- MCRB 05-07-2025
- Dividend Yield
- TEAF 9.20%
- MCRB N/A
- EPS Growth
- TEAF N/A
- MCRB N/A
- EPS
- TEAF N/A
- MCRB 0.00
- Revenue
- TEAF N/A
- MCRB N/A
- Revenue This Year
- TEAF N/A
- MCRB N/A
- Revenue Next Year
- TEAF N/A
- MCRB N/A
- P/E Ratio
- TEAF N/A
- MCRB $474.36
- Revenue Growth
- TEAF N/A
- MCRB N/A
- 52 Week Low
- TEAF $11.11
- MCRB $0.46
- 52 Week High
- TEAF $13.30
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- TEAF 47.96
- MCRB 28.34
- Support Level
- TEAF $10.09
- MCRB $0.36
- Resistance Level
- TEAF $11.58
- MCRB $0.67
- Average True Range (ATR)
- TEAF 0.25
- MCRB 0.07
- MACD
- TEAF 0.04
- MCRB -0.02
- Stochastic Oscillator
- TEAF 68.46
- MCRB 2.71
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.